How to control recurrent angioedema using monoclonal antibody therapies?

References

• Buttgereit T, Maurer M. Classification and pathophysiology of angioedema. Hautarzt. 2019 Feb;70(2):84–91.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Metz M, et al. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy. 2013 Jun;68(6):816–819.
   PubMed Web of Science ®Google Scholar
• Carvalho D, Aguiar P, Ferrinho P, et al. Eczema and Urticaria in the adult population in Portugal: a prevalence study. Actas Dermo-sifiliograficas. 2019 May;110(9):744–751.
   PubMed Web of Science ®Google Scholar
• Weller K, Altrichter S, Ardelean E, et al. Chronic urticaria prevalence, course, prognostic factors and impact. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete. 2010 Sep;61(9):750–757.
   PubMed Web of Science ®Google Scholar
• Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria. Immunol Rev. 2018 Mar;282(1):232–247.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Schmetzer O, et al. Immunoglobulin E-mediated autoimmunity. Front Immunol. 2018;9:689.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017 Jun;139(6):1772–1781.e1.
   PubMed Web of Science ®Google Scholar
• Sussman G, Abuzakouk M, Berard F, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy. 2018 Aug;73(8):1724–1734.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy. 2014 May;69(5):602–616.
   PubMed Web of Science ®Google Scholar
• Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017 Dec;72(12):2005–2016.
   PubMed Web of Science ®Google Scholar
• Schulkes KJG, Van Den Elzen MT, Hack EC, et al. Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study. Clin Transl Allergy. 2015;5(1):5.
   PubMedGoogle Scholar
• Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens (Greenwich). 2017 Dec;19(12):1377–1382.
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Magerl M, Maetzel A, et al. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018 May 4;13(1):73.
   PubMedGoogle Scholar
• Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010 Sep-Oct;31(5):407–414.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012 Oct;67(10):1289–1298.
   PubMed Web of Science ®Google Scholar
• Weller K, Magerl M, Peveling-Oberhag A, et al. The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016 Aug;71(8):1203–1209.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 Jul;73(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score. Allergy. 2013 Sep;68(9):1185–1192.
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018 Mar;73(3):576–584.
   PubMed Web of Science ®Google Scholar
• Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol. 2017 Dec;140(6):1710–1713.e11.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014 May;133(5):1365–72, 1372.e1–6.
   PubMed Web of Science ®Google Scholar
• Weller K, Donoso T, Magerl M, et al. Development of the Angioedema Control Test (AECT) - a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy Asthma Clin Immunol. 2019. Under review.
   Google Scholar
• Metz M, Scholz E, Ferran M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010 Jan;104(1):86–92.
   PubMed Web of Science ®Google Scholar
• Salman A, Demir G, Bekiroglu N. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: real-life data. Dermatologic Therapy. 2019 May;30:e12975.
   Google Scholar
• Maurer M, Sofen H, Ortiz B, et al. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1056–1063.
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016 Aug;71(8):1135–1144.
   PubMed Web of Science ®Google Scholar
• Bucher MC, Petkovic T, Helbling A, et al. Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. Clin Transl Allergy. 2017;7:27.
   PubMed Web of Science ®Google Scholar
• Faisant C, Du Thanh A, Mansard C, et al. Idiopathic non-histaminergic angioedema: successful treatment with omalizumab in five patients. J Clin Immunol. 2017 Jan;37(1):80–84.
   PubMed Web of Science ®Google Scholar
• Azofra J, Diaz C, Antepara I, et al. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015 May;114(5):418–9 e1.
   PubMed Web of Science ®Google Scholar
• Kocaturk E, Zuberbier T. New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):425–431.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug; 23. [Epub ahead of print].
   Google Scholar
• Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019 Oct 3;381(14):1321–1332.
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019 May;29. [Epub ahead of print].
   Google Scholar
• Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges. 2018 Apr;16(4):477–478.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):e112–e113.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Aug;73(8):1575–1596.
   PubMed Web of Science ®Google Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018 Nov 27;320(20):2108–2121.
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018 Jul 26;379(4):352–362.
   PubMed Web of Science ®Google Scholar
• Behring C. multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE. ClinicalTrials. gov2018 [assessed 15th of October 2019]. Available from https://clinicaltrials.gov/ct2/show/NCT03712228?term=NCT03712228&rank=1
   Google Scholar